Table 6.
Antihypertensive efficacy of amlodipine in patients with rs1045642 ABCB1 polymorphisms
| Antihypertensive efficacy criteria | Total number per group (n=100) | CC (n=17) | CT (n=53) | TT (n=30) | Intergroup differences, Mann–Whitney U test, P-value
|
Intergroup differences, Kruskal–Wallis one-way ANOVA, P-value | ||
|---|---|---|---|---|---|---|---|---|
| CC vs CT | CC vs TT | CT vs TT | ||||||
| Patients with a normalization of BP (reduction of SBP <140 mmHg, DBP <90 mmHg) | 33 (33) | 2 (11.8%) | 18 (34.0%) | 13 (43.3%) | 0.02 | 0.02 | 0.05 | 0.04 |
| Patients with reduction of SBP ≥20 mmHg and/or DBP ≥10 mmHg | 33 (33) | 6 (35.3%) | 17 (32.0%) | 10 (33.3%) | 0.35 | 0.5 | 0.35 | 0.04 |
| Patients with reduction of SBP <20 mmHg and/or DBP <10 mmHg | 34 (34) | 9 (52.9%) | 18 (34.0%) | 7 (23.4%) | 0.02 | 0.04 | 0.05 | 0.04 |
| Patients who required dosage increase | 34 (34) | 9 (52.9%) | 18 (34.05) | 7 (23.4%) | 0.02 | 0.04 | 0.05 | 0.04 |
Note: Data are reported as mean ± SD.
Abbreviation: BP, blood pressure.